rom Terminal to Treatable
LifeBridge redefines metastatic cancer treatment, turning once-terminal diagnoses into manageable conditions—without side effects.
Current Status
IP Advantage
5 US Patents! 10 more pending plus EU, Australia, New Zealand, Canada, Mexico, Chile, China, Japan, and Luxembourg!
Freedom to operate opinion
All IP is owned by LifeBridge
Regulatory & Go-to-Market Advantage
FDA “Basket Trial” design
Fast-Follower Strategy: low-risk commercial & clinical trial strategy
Fully human wearable device
Completing FDA requirement (animal study active0
Problem or Opportunity
90% of all cancer deaths are from metastatic cancer, not primary tumors. Huge global problem. In the next 36 months 21.6 million people will die form metastatic cancer
> All forms of therapies fail these patients including chemo, radiation and surgery
>Metastatic Cancer outcomes are getting worse for progressive Breast Cancer patients
>Deaths are often excruciating
>Patients and their doctors are desperately seeking high quality extended life
Solution (product or service)
LifeBridge’s Patented adaptive tumor treating fields (ATTF), Unmasks cancer cells to a patient’s own immune system, causing cancer cell death and tumor reduction, with no side effects. The results is designed to transform metastatic cancer from a terminal illness to a manageable one with a high quality of life
Business model
Oncologists prescribe our device, patients wear the device for designated times daily, 3rd party reimbursement. The existing form of tumor treating fields has secured 3rd party reimbursement globally
Incubation/Acceleration programs accomplishment
Member University of Central Florida Business Incubator
Cenfluence Life Science group Orange county Florida
Johnson and Johnsons JLABS DC
